Jyong Biotech (MENS) Registration Filing summary

Company overview and business model

• Science-driven biotech firm based in Taiwan, focused on developing and commercializing innovative plant-derived drugs for urinary system diseases, targeting the U.S., EU, and Asia markets.

• Operates through five wholly owned subsidiaries in Taiwan, Singapore, Hong Kong, and China; holding company structure in the Cayman Islands.

• Core pipeline includes MCS-2 (for BPH/LUTS), PCP (prostate cancer prevention), and IC (interstitial cystitis), with MCS-2 as the lead candidate.

• Integrated in-house capabilities span drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization.

Financial performance and metrics

• No revenue generated to date; net losses of $6.6M (2022), $4.4M (2023), and $1.3M (first half 2024).

• Accumulated deficit of $31.4M as of June 30, 2024; net working capital deficit of $11.7M.

• Research and development expenses were $1.3M (2022), $1.1M (2023), and $0.5M (first half 2024).

• Cash and cash equivalents of $96K as of June 30, 2024; significant reliance on debt and related party loans.

• Auditor and management have raised substantial doubt about the company’s ability to continue as a going concern.

Use of proceeds and capital allocation

• Proceeds will primarily fund Phase III trials and NDA for MCS-2 (40%), earlier phase trials if comparability is not demonstrated (25%), Phase II trial for PCP (10%), Phase I trial for IC (5%), and general corporate purposes (20%).

• A portion of proceeds will address litigation settlements and commitments related to Taizhou legal disputes.

• Additional capital of ~$10M will be needed to complete development and commercialization of drug candidates.